The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. A final decision is expected in the coming months.
University Hospitals Cleveland Medical Center has announced a collaboration with global healthcare AI company Qure.ai to deploy chest X-ray AI supporting earlier identification of lung cancers.
